Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobs INDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today broke ground on a $3.5 billion manufacturing facility in Pennsylvania's...
Covered in this story
Analyst targets on Lilly (Eli)
- Freedom Broker: at $1.42k · target $1.6k by Oct 2027 · Buy via Investing.com
- Bernstein: at $1.42k · target $1.45k by Oct 2027 · Outperform via Investing.com
- BMO Capital Markets: at $1.42k · target $1.65k by Oct 2027 · Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LLY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lilly (Eli) →Dalsna Finance is currently tracking 6 stories mentioning Lilly (Eli), the earliest published 9 Sept 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.